+1-518-621-2074 | US-Canada Toll Free Contact Us

Autologous Cell Therapy - Geriatric Population Fueling Market Growth

about us

Published on : Mar 18, 2020

ResearchMoz.us has announced the addition of a report, titled “Global Autologous Cell Therapy Market Size, Status and Forecast 2019-2025”. The report on the global Autologous Cell Therapy market offers an elaborate assessment of key growth trends and drivers, recent developments in the market, the competitive ecosystem, and opportunity and challenges analysis. Segments in the report are created by product type and application.

The market report is segmented based on type, application, and region. By types, it has sub-segments on epidermis and bone marrow. And, by application, the sub segments include wound healing, cancer, neurology, and orthopedics.

The reasons fueling growth in the global autologous cell therapy market are multiple and include the likes of increase in incidence of cancer, neurological disorders, surgeries, orthopedic disorders etc. And, one of the major factors behind growth in rising incidences of health conditions is the rapidly rising geriatric population.

One in every six people in the world will be old by the year 2050, falling in the age group of 65 and above. And, one in every four people will occupy this bracket in North America and Europe. As per a study in the next 30 years, the number of people aged 60 and above will be a massive two billion. This is quite a notable rise from the year 2015, in which the number of people in this age group was 900 million.

This demographic is susceptible to these disorders and any injuries or wounds from surgeries take a longer time and much efforts to heal, driving growth in the global autologous cell therapy market. An interesting fact here is the dramatic demographic shift witnessed in the year 2018 which was historic. For the first time in human history, population of people aged 65 and above was higher than those aged five and below.

Also, incidence of cancer has a part to play in the global autologous cell therapy market. To get a fair picture, some statistics might help. For instance, in middle and low income countries, 70% deaths result from this menace. And, thus, it does not surprise anyone to note that it is the second leading cause of deaths on a global level. In fact, in the year of 2018, about 9.6 million deaths. That roughly translates to one in six deaths globally.

Request a Sample PDF copy with detailed Insights: https://www.researchmoz.us/enquiry.php?type=S&repid=2404843

One of the leading causes of this increase in the incidence of cancer is the deteriorating lifestyle of people. Due to poor dietary habits, tobacco and alcohol use, obesity and lack of physical activity, susceptibility to certain types of cancer increase. Deaths from these cancers come up to a one-third of the total.

It is all worth noting here that some infections such as HPV and hepatitis causes cancer in middle and low income countries – up to 25% of cases. 

It is pertinent to note here that autologous cell therapy obliterates the need for immunosuppression as it uses stem cells from the same person to culture and then inject it back. The person receiving the transplant is the same from whom these cells are harvested. Consequently, chances of the treatment failing go down. 

The global autologous cell therapy market is consolidated and some of the key players in the market landscape include BioTime, Pharmicell, BrainStorm Cell Therapeutics, Opexa Therapeutics, Vericel Corporation, and Regeneus. The report has a comprehensive profile of these players - market share, strategies, and other such critical information that can pave way for growth in the future. Major strategies deployed by players include collaborations and partnerships, and mergers and acquisitions.